premargin

Element List	Explanation
Announcement Detail	Qomel Co. announces to its valued shareholders that on 29 January 2026, its subsidiary, Qomel Factory Company, located in Sudair Industrial City and specialized in the production of pharmaceutical products in the form of tablets and capsules, has obtained the Good Manufacturing Practice (GMP) Certificate issued by the Saudi Food and Drug Authority (SFDA). The GMP certificate covers the packaging stage of human pharmaceutical products, following the factory’s fulfillment of the Authority’s requirements and compliance with locally approved standards. The Company also announces the commencement of the trial operation of Qomel Factory, as a preparatory step toward transitioning to the commercial operation stages in accordance with the approved plans. The Company expects that the positive financial impact resulting from this development will begin to appear during the first half of 2026, following the completion of commercial operation phases and the stabilization of production capacity. This achievement comes as part of Qomel Company’s strategy aimed at enhancing its manufacturing capabilities, localizing pharmaceutical manufacturing, and supporting pharmaceutical supply chains within the Kingdom, in line with the objectives of Saudi Vision 2030

Element List

Explanation

Announcement Detail

Qomel Co. announces to its valued shareholders that on 29 January 2026, its subsidiary, Qomel Factory Company, located in Sudair Industrial City and specialized in the production of pharmaceutical products in the form of tablets and capsules, has obtained the Good Manufacturing Practice (GMP) Certificate issued by the Saudi Food and Drug Authority (SFDA).

The GMP certificate covers the packaging stage of human pharmaceutical products, following the factory’s fulfillment of the Authority’s requirements and compliance with locally approved standards.

The Company also announces the commencement of the trial operation of Qomel Factory, as a preparatory step toward transitioning to the commercial operation stages in accordance with the approved plans.

The Company expects that the positive financial impact resulting from this development will begin to appear during the first half of 2026, following the completion of commercial operation phases and the stabilization of production capacity.

This achievement comes as part of Qomel Company’s strategy aimed at enhancing its manufacturing capabilities, localizing pharmaceutical manufacturing, and supporting pharmaceutical supply chains within the Kingdom, in line with the objectives of Saudi Vision 2030

Qomel Co. Announces That Its Subsidiary (Qomel Factory) Has Obtained Good Manufacturing Practice (GMP) Certification for the Packaging Stage and the Commencement of Trial Operation